Phase II Trial of Motexafin Gadolinium and Pemetrexed (Alimta) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer.
Phase of Trial: Phase II
Latest Information Update: 02 Nov 2016
At a glance
- Drugs Motexafin gadolinium (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Pharmacyclics
- 24 Oct 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 19 Aug 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 13 Mar 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov.